Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
UDP glucuronosyltransferase family 1 member A1 | 0.464 | 0.769 | 3.3E-06 |
|
disease | 1.000 | None | 0.984 | 2 | 0 | 1992 | 2019 | ||||||||
|
secreted LY6/PLAUR domain containing 1 | 0.560 | 0.654 | 0.26 |
|
disease | 1.000 | strong | 0.973 | 2 | 0 | 2001 | 2019 | ||||||||
|
sarcoglycan alpha | 0.592 | 0.654 | 2.7E-03 |
|
disease | 1.000 | None | 1.000 | 2 | 0 | 1994 | 2019 | ||||||||
|
serine/threonine kinase 11 | 0.435 | 0.808 | 0.99 |
|
disease | 1.000 | definitive | 0.992 | 2 | 0 | 1997 | 2019 | ||||||||
|
transforming growth factor beta receptor 1 | 0.451 | 0.885 | 0.85 |
|
disease | 1.000 | definitive | 1.000 | 2 | 0 | 1993 | 2019 | ||||||||
|
transforming growth factor beta receptor 2 | 0.413 | 0.846 | 0.13 |
|
disease | 1.000 | strong | 1.000 | 2 | 0 | 2003 | 2019 | ||||||||
|
transglutaminase 1 | 0.565 | 0.769 | 2.3E-13 |
|
disease | 1.000 | limited | 1.000 | 2 | 0 | 1994 | 2019 | ||||||||
|
EPM2A glucan phosphatase, laforin | 0.608 | 0.577 | 8.7E-06 |
|
disease | 1.000 | None | 0.965 | 2 | 0 | 1998 | 2020 | ||||||||
|
fibroblast growth factor 23 | 0.460 | 0.731 | 3.1E-02 |
|
disease | 1.000 | strong | 1.000 | 2 | 0 | 2000 | 2020 | ||||||||
|
solute carrier family 4 member 11 | 0.674 | 0.385 | 4.6E-15 |
|
disease | 1.000 | None | 1.000 | 2 | 0 | 2006 | 2020 | ||||||||
|
PHD finger protein 6 | 0.581 | 0.692 | 1.00 |
|
disease | 1.000 | definitive | 1.000 | 2 | 0 | 2002 | 2020 | ||||||||
|
cellular communication network factor 6 | 0.568 | 0.731 | 6.2E-04 |
|
disease | 1.000 | strong | 0.968 | 2 | 0 | 1999 | 2019 | ||||||||
|
nuclear receptor subfamily 2 group E member 3 | 0.603 | 0.500 |
|
disease | 1.000 | None | 0.974 | 1 | 0 | 2000 | 2019 | |||||||||
|
retinoic acid induced 1 | 0.545 | 0.731 | 1.00 |
|
disease | 1.000 | definitive | 0.981 | 1 | 0 | 2001 | 2019 | ||||||||
|
CF transmembrane conductance regulator | 0.424 | 0.885 | 2.2E-58 |
|
disease | 1.000 | None | 0.979 | 1 | 0 | 1989 | 2020 | ||||||||
|
serine peptidase inhibitor Kazal type 5 | 0.604 | 0.654 | 4.8E-28 |
|
disease | 1.000 | strong | 0.982 | 1 | 0 | 2000 | 2019 | ||||||||
|
lysosomal trafficking regulator | 0.621 | 0.692 | 1.5E-02 |
|
disease | 1.000 | None | 0.982 | 1 | 0 | 1968 | 2019 | ||||||||
|
EF-hand domain containing 1 | 0.659 | 0.231 | 1.9E-17 |
|
disease | 1.000 | disputed | 0.979 | 1 | 0 | 1993 | 2019 | ||||||||
|
C1q and TNF related 5 | 0.663 | 0.346 | 0.84 |
|
disease | 1.000 | None | 1.000 | 1 | 0 | 2003 | 2019 | ||||||||
|
tripeptidyl peptidase 1 | 0.551 | 0.808 | 6.3E-07 |
|
disease | 1.000 | None | 1.000 | 1 | 0 | 1997 | 2019 | ||||||||
|
CLN3 lysosomal/endosomal transmembrane protein, battenin | 0.572 | 0.692 | 1.3E-07 |
|
disease | 1.000 | None | 0.994 | 1 | 0 | 1990 | 2019 | ||||||||
|
collagen type I alpha 1 chain | 0.430 | 0.808 | 1.00 |
|
disease | 1.000 | None | 0.976 | 1 | 0 | 1988 | 2019 | ||||||||
|
collagen type II alpha 1 chain | 0.444 | 0.846 | 1.00 |
|
disease | 1.000 | None | 1.000 | 1 | 0 | 1988 | 2012 | ||||||||
|
collagen type II alpha 1 chain | 0.444 | 0.846 | 1.00 |
|
disease | 1.000 | None | 0.981 | 1 | 0 | 1989 | 2020 | ||||||||
|
collagen type VI alpha 3 chain | 0.563 | 0.769 | 1.8E-20 |
|
disease | 1.000 | strong | 1.000 | 1 | 0 | 2002 | 2018 |